Haemonetics
314 hedge funds and large institutions have $3.44B invested in Haemonetics in 2025 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 127 increasing their positions, 102 reducing their positions, and 46 closing their positions.
29% more call options, than puts
Call options by funds: $26M | Put options by funds: $20.1M
25% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 102
17% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 46
2% more funds holding
Funds holding: 309 → 314 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.75% less ownership
Funds ownership: 112.62% → 107.88% (-4.7%)
22% less capital invested
Capital invested by funds: $4.42B → $3.44B (-$973M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$94.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$25.1M |
| 4 |
Citigroup
New York
|
+$19.8M |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$181M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$89.5M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$85.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$62.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$24.4M |
HAE Hedge Fund Activity: Q1 2025 in Review
314 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2025, worth a combined $3.44B — down 22% from $4.42B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new HAE positions and 46 closed out — a net gain of 8 holders — while 127 added to existing stakes and 102 trimmed.
The largest buyer was River Road Asset Management, opening a new position worth an estimated $94.9M. The largest seller was Capital Research Global Investors, cutting an estimated $181M.
- 314 institutional investors held Haemonetics (HAE) as of Q1 2025, up from 309 in Q4 2024.
- Funds reported $3.44B of Haemonetics stock for Q1 2025, down 22% quarter-over-quarter.
- 54 funds opened new Haemonetics positions in Q1 2025 and 46 closed out, a net change of +8 holders.
- The largest Haemonetics buyer in Q1 2025 was River Road Asset Management, an estimated $94.9M added.
- The largest Haemonetics seller in Q1 2025 was Capital Research Global Investors, an estimated $181M sold.
Based on aggregated 13F filings for Q1 2025.